Hematologic Oncology | Oncology Today with Dr Neil Love: Key Presentations on Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2020 ASH Annual Meeting

Research To Practice | Oncology Videos

Featuring an interview with Dr Harry Paul Erba, including the following topics:

• Improvement in overall survival in the VIALE-A trial with azacitidine/venetoclax compared to azacitidine alone for patients with previously untreated acute myeloid leukemia (AML) ineligible for intensive chemotherapy (0:00)
• Delay in time to deterioration of health-related quality of life for patients with AML receiving venetoclax in combination with azacitidine or low-dose cytarabine (2:26)
• Interim analysis of the Phase Ib/II study of venetoclax with FLAG-IDA for patients with newly diagnosed or relapsed/refractory (R/R) AML (4:12)
• High rates of minimal residual disease-negative complete remission and excellent tolerability with venetoclax added to cladribine and low-dose ara-C alternating with 5-azacitidine for newly diagnosed AML in older patients (7:14)
• Final results of a Phase III study evaluating CPX-351 versus 7 + 3 for older adults with newly diagnosed high-risk or secondary AML (8:39)
• Phase II study of CPX-351 with venetoclax for patients with AML (11:07)
• Results with venetoclax and azacitidine for chemotherapy-ineligible patients with untreated AML with IDH1/2 mutations (18:00)
• Improvement in overall survival with ivosidenib compared to standard therapies for relapsed or refractory AML with IDH1 mutation (22:26)
• Beat AML Master Trial: Enasidenib monotherapy with the addition of azacitidine for nonresponders is effective in older patients with newly diagnosed AML with IDH2 mutations (24:48)
• Efficacy of gilteritinib in patients with R/R AML harboring FLT3 mutations (26:46)
• Clinical outcomes for patients with R/R AML treated with gilteritinib who received prior midostaurin or sorafenib (30:17)
• Difference in patterns of secondary resistance between Type I and Type II FLT3 inhibitors in patients with AML (31:33)
• Final results of a Phase I study of gilteritinib in combination with induction and consolidation chemotherapy for patients with newly diagnosed AML (34:21)
• Phase III LACEWING study of gilteritinib, gilteritinib with azacitidine or azacitidine alone for patients with newly diagnosed AML with FLT3 mutations who are ineligible for intensive induction chemotherapy (35:28)
• Efficacy and safety of venetoclax in combination with gilteritinib in patients with R/R AML with FLT3 mutations in the expansion cohort of a Phase Ib study (38:27)
• Phase Ib results with the first-in-class anti-CD47 antibody magrolimab combined with azacitidine for AML (41:29)
• Results from the QUAZAR AML-001 maintenance trial of CC-486 for patients with AML (46:00)
• BMT CTN 1102 trial comparing reduced-intensity allogeneic hematopoietic cell transplantation to hypomethylation therapy or best supportive care for patients aged 50 to 75 with advanced myelodysplastic syndromes (MDS) (51:45)
• Health-related quality-of-life outcomes for patients with MDS with ring sideroblasts treated with luspatercept in the MEDALIST study (56:52)
• Interim analysis of the Phase III European SINTRA-REV trial of lenalidomide for patients with low-risk del(5q) MDS who are not transfusion dependent (1:01:26)
• Safety, efficacy and patient-reported outcomes with venetoclax in combination with azacitidine for patients with higher-risk MDS (1:04:38)
• Efficacy and safety of pevonedistat and azacitidine compared to azacitidine alone for patients with higher-risk MDS in the Pevonedistat-2001 trial (1:08:53)
• Conclusions in AML and MDS from 2021 Highlights of ASH® (1:11:19)

CME information and select publications